Assentia has unveiled two new proprietary, SaaS-based applications, GrantPay™ and GrantPact™, designed to aid Assentia in merging its global knowledge in clinical trial contract negotiations and investigative site payments with functional technology platforms.
Assentia utilizes GrantPay™ to provide investigator site payments on a multi-currency, global scale in addition to granular forecasting and customizable reporting to assist its clients' needs and obligations.
GrantPact™ is Assentia's proprietary platform supporting its international team in negotiating and tracking global clinical trial agreements, including housing previously negotiated legal clauses with study sites worldwide.
Assentia Unveils Proprietary Software, GrantPay™ and GrantPact™, to Aid in Accelerating Clinical Trial Study-Startup and Investigator Payments. (2023, March 9). Cision PR Newswire.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.